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AbstrACt
Introduction Therapeutic schedules for treating 
neonatal seizures remain elusive. First-line treatment 
with phenobarbital is widely supported but without 
strong scientific evidence. Levetiracetam (LEV) is an 
emerging and promising antiepileptic drug (AED). The 
aim of this phase II trial is to determine the benefits of 
LEV by applying a strict methodology and to estimate 
the optimal dose of LEV as a first-line AED to treat 
seizures in newborns suffering from hypoxic-ischaemic 
encephalopathy.
Methods and analysis LEVNEONAT-1 is an open and 
sequential LEV dose-finding study. The optimal dose is 
that which is estimated to be associated with a toxicity 
not exceeding 10% and an efficacy higher than 60%. 
Efficacy is defined by a seizure burden reduction of 80% 
after the loading dose. Four increasing dose regimens 
will be assessed including one loading dose of 30, 40, 
50 or 60 mg/kg followed by eight maintenance doses (ie, 
a quarter of the loading dose) injected every 8 hours. A 
two-patient cohort will be necessary at each dose level 
to consider an upper dose level assignment. The maximal 
sample size expected is 50 participants with a minimum of 
24 patients or fewer in the case of a high rate of toxicity. 
Patients will be recruited in five neonatal intensive care 
units beginning in October 2017 and continuing for 2 years. 
In parallel, the LEV pharmacokinetics will be measured 
five times (ie, 30 min; 4 and 7 hours after the loading dose; 
1–3 hours and 12–18 hours after the last maintenance 
dose).
Ethics and dissemination Ethics approval has been 
obtained from the regional ethical committee (2016-R25) 
and the French Drug Safety Agency (160652A-31). The 
results will be published in a peer-reviewed journal. The 
results will also be presented at medical meetings.
trial registration number NCT02229123; Pre-results.
IntroduCtIon  
Neonatal seizures occur in approximately 1 
to 5 per 1000 live births.1 Hypoxic-ischaemic 
encephalopathy (HIE) represents the first 
aetiology of neonatal seizures.1 2 In 80% of 
cases, seizures associated with HIE occur in the 
first 3 days of life.2 Seizure treatment during 
the neonatal period creates issues concerning 
the developing brain facing deleterious 
effects of seizure burden (SB) to the potential 
toxicity of conventional antiepileptic drugs 
(AED). Van Rooij et al demonstrated that the 
seizure duration was correlated with brain 
lesions through MRI.3 Therefore, the World 
Health Organisation recommended in 2011 
that anticonvulsant treatment should be initi-
ated immediately when clinically apparent 
seizures have lasted for longer than 3 min or 
strengths and limitations of this study
 ► For the first time, levetiracetam (LEV) will be used as 
first-line treatment for neonatal seizures rather than 
as an add-on therapy.
 ► The targeted population (ie, newborns less than 3 
days old) is particularly vulnerable, and the ethical 
authority requires the written consent of both par-
ents before LEV administration.
 ► The restricted availability of electroencephalogram 
(EEG) devices in each investigating centre led after 
the cessation of seizure burden to a minimal re-
quirement of a 1 hour EEG recording on days 1, 2, 
3 and 6.
 ► The statistical model is designed for a rare clinical 
situation with a sequential adaptive method, which 
updates in real time the dose allocation for the next 
patient based on all available data from previous 
participants.
 ► On average, the proposed design prompts recom-
mendations of the correct dose at approximately 
60% of efficacy for a sample size of 30, increasing to 
over 80% in many scenarios for a sample size of 50.
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in the case of brief repeated seizures. This recommenda-
tion was supported strongly but no gradation was attribut-
able due to the lack of scientific evidence.4 Furthermore, 
conventional AEDs such as phenobarbital (PHB) are 
employed in an off-label manner in neonates. Epidemi-
ological studies have illustrated that PHB is widely used 
as the first-line treatment across the world with a lack of 
consensus concerning subsequent add-on lines of treat-
ment, including phenytoin (PHT), lidocaine, midazolam 
and other benzodiazepines.5 A meta-analysis from the 
Cochrane Database concluded in 2004 that ‘there is little 
evidence from randomised controlled trials to support 
the use of any of the anticonvulsants currently used in the 
neonatal period’. This statement was recently reinforced 
by a systematic review published in 2015, which presumed 
that ‘there is an urgent need for more evidence-based 
studies to guide neonatal seizure management’.5 6 This 
vague position resulted from the lack of well-conducted 
trials and from the limited available data regarding the 
efficacy and safety of AED use during the neonatal period. 
Only one randomised controlled trial was performed 
focusing on AED efficacy in neonates. In this trial, PHB as 
PHT precipitated seizure cessation in only 44% of cases in 
monotherapy. The SB intensity appeared to be inversely 
related to therapeutic success.7 This restricted efficacy 
might be explained by the signalling pathway of PHB on 
GABA receptors, which are paradoxically excitatory in 
the immature brain before transitioning to their inhibi-
tory function.8 9 Furthermore, recurrent seizures induced 
an intracellular chloride accumulation, reinforcing 
the excitatory function of GABA receptors and then 
creating PHB inefficiency in treating intense SB during 
the neonatal period.10 Moreover, some concerns about 
the safety of PHB exist. Experimental data have demon-
strated that PHB increased in a dose-dependent manner 
neuronal apoptosis in the immature brain.11 Therefore, 
a necessity for new efficient and safe AEDs for newborns 
has emerged. Levetiracetam (LEV) might be the appro-
priate candidate to fulfil these criteria. First, LEV exhibits 
an original means of action by reducing, through the 
SV2a protein, glutamate release by presynaptic neurons 
and then regulating the intracellular calcium of postsyn-
aptic neurons through NMDA and AMPA receptors.12 
Second, LEV appears to be free of toxicity in relation 
to the neonatal brain. Experimental data have demon-
strated that LEV did not induce neuronal apoptosis in the 
neonatal brain.13 14 Furthermore, an observational study 
illustrated that LEV cumulative doses received during the 
neonatal period were not associated with the probability 
of subsequently developing a cerebral palsy.15 Third, an 
intravenous galenic form of LEV is available, allowing for 
the treatment of non-fed newborns. Fourth, an off-label 
use of LEV as second-line treatment after PHB has now 
been widely observed.16 17 Retrospective studies reported 
LEV use in neonates with various dose regimens and 
administration schedules such as increasing doses until 
seizure cessation, similar doses twice a day, or a loading 
dose with subsequent maintenance doses. Loading doses 
infused to neonates varied from 10 mg/kg to 60 mg/
kg.17–25 The maximal amount of LEV infused in a newborn 
was 150 mg/kg within a 24 hours period.17 Fifth, to date, 
the treatment of approximately 445 newborns through 
LEV has been reported with limited side effects including 
one case of anaphylactic shock and a rare sleepy state 
fostered by a simultaneous PHB treatment.19 22 23 26 27 
Similarly, LEV efficacy for significantly reducing or elim-
inating neonatal seizures has been recently estimated at 
77% of cases in first-line treatment and 66% of cases in 
add-on therapy in a cohort of 102 patients from five retro-
spective studies.28 In this context, it is highly important 
to determine the benefits of LEV for treating neonatal 
seizures and to determine the most effective and safest 
dose of LEV in neonates following a rigorous and prospec-
tive methodology. In this study, a phase II trial has been 
designed to identify the ideal LEV loading and mainte-
nance doses in newborns suffering from HIE. An original 
approach has been adopted by using LEV as the first-line 
treatment.
MEthods And AnAlysIs
study settings
Patient recruitment will be performed in five French 
Neonatal Intensive Care Units (NICU) (Angers, Lille, 
Rouen, Rennes and Tours) beginning in October 2017 and 
continuing for 2 years. These centres have been selected 
for their expertise in managing neonatal seizures. The 
coordinating site for this study is the University Hospital 
Center of Tours (France). The protocol has been written 
according to the SPIRIT reporting guidelines.29
Participants
Eligible patients are term newborns with hypoxic isch-
aemic encephalopathy (HIE) who are less than 72 hours 
old (figure 1). Briefly, three inclusion criteria have been 
selected: (i) birth term above 36 gestational weeks and 
birth weight above 1800 g; (ii) perinatal asphyxia, defined 
as Apgar score equal to or below five at 5 min, resuscita-
tion required at birth or metabolic acidosis on umbilical 
arterial blood gas or until 1 hour after birth (pH <7.1, 
Excess Base ≥16 mmol/L or lactate ≥11) and (iii) neuro-
logical impairment in the first 6 hours of life, including 
consciousness, tone, sucking, archaic reflexes or pupillary 
alterations.
Brain cooling implementation is delegated entirely to 
the discretion of investigators according to the French 
guidelines.30 Therapeutic hypothermia implementation 
and the rewarming time will be reported in the e-CRF 
form. Since seizures generally occur during moderate 
and severe HIE requiring therapeutic hypothermia, it 
is expected that most participants are on brain cooling. 
Therapeutic hypothermia is regarded as a variable in the 
pharmacokinetic analysis.
Inclusion should be considered when clinical signs 
or an electroencephalogram (EEG) pattern compatible 
with seizures are recognised by the investigator and when 
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monitoring with a continuous 8-electrode EEG recording 
is possible. A seizure lasting more than 3 min or more 
than two seizures lasting more than 20 s within a 1-hour 
period on a standard EEG recording fulfils the inclusion 
criteria. Critical-activity recognition on EEG recording is 
based on the investigator’s experience. A specific training 
for recognising critical activity on standard EEG has been 
provided to the investigators in each centre. An inclusion 
could be diagnosed incorrectly by a retrospective inter-
pretation of an EEG recording by a local electrophysi-
ologist planned as soon as possible (cf. Efficacy Criteria). 
A second interpretation by an independent and blind 
reader will be organised in a brief delay to assess the lack 
of critical activity on the EEG recording. If the lack of crit-
ical activity on the EEG is confirmed, the patient will not 
be included in the statistical model and the experimental 
treatment will be immediately disrupted, but pharma-
cokinetic and safety analysis will be performed. Finally, 
written consent of both parents or authorised guardians 
and a subscription to social security health insurance are 
required to complete inclusion.
Figure 1 LEVNEONAT-1 study flowchart. AED, antiepileptic drug; EEG, electroencephalogram; GW, gestational weeks; LEV, 
levetiracetam; T0, levetiracetam loading dose infusion start; T11/4, 1 hour and 15 min after the levetiracetam loading dose 
infusion start; T41/4, 4 hours and 15 min after the levetiracetam loading dose infusion start.
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Exclusion criteria concern patients already treated with 
an AED aside from a midazolam bolus required for intu-
bation, patients suffering from seizures due to a treatable 
metabolic aetiology such as hypoglycaemia and hypocal-
caemia, patients with severe renal failure associated with 
serum creatinine above 150 µmol/L, patients with evident 
signs of genetic or congenital malformations or infectious 
embryofoetopathy or patients who have already been 
recruited in another interventional research trial.
Intervention
A therapeutic schedule consists of a loading dose (T0) 
followed by eight maintenance doses every 8 hours 
resulting in a 3-day treatment period (figure 2). Eight-
hour intervals between doses were implemented based 
on the LEV pharmacokinetics (PK) obtained from 18 
newborns, demonstrating a shorter half-life of 8.9 hours 
relative to older patients.26 Four increasing loading doses 
were selected as follows: (i) 30 mg/kg; (ii) 40 mg/kg; (iii) 
Figure 2 LEVNEONAT-1 experimental schedule and time-line. AED, antiepileptic drug; AEP, auditory evoked potentials; EEG, 
electroencephalogram; EFF, efficacy; LEV, levetiracetam; PK, pharmacokinetic; TOX, toxicities.
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50 mg/kg and (iv) 60 mg/kg. Each maintenance dose 
corresponds with a quarter of the loading dose (7.5, 10, 
12.5 and 15 mg/kg, respectively). Levetiracetam (leve-
tiracetam Mylan, 100 mg/mL) will be diluted in a 5% 
glucose solution to a final concentration of 5 mg/mL. 
LEV will be administered intravenously over a fixed time 
of 15 min through a central or peripheral line.
Principal aim
The principal aim is to determine the most efficient dose 
regimen under toxicity restrictions of LEV for neonates 
while accounting for efficacy, toxicity and PK.
Efficacy criteria
Efficacy has been defined as an 80% reduction of SB in an 
EEG recording between the period immediately before 
the LEV loading dose (from 20 min to 3 hours) and the 
3 hour time interval from 1 hour and 15 min (T11/4) to 
4 hours and 15 min (T41/4) after the beginning of loading 
dose infusion (T0) (figure 2). SB corresponds with the 
cumulative time of ictal electric activity on the EEG- anal-
ysed time lap. A first analysis of the EEG recording will be 
performed locally at each investigator centre and will be 
reported in e-CRF format on the sixth day following T0. 
A second blinded and centralised analysis is scheduled to 
occur subsequently, every 6 months. If there is more than 
a 10% difference between EEG interpreters or an oppo-
site conclusion, a third EEG analysis will be performed. A 
subsequent correction of efficacy criteria in the statistical 
model can be performed (whenever it is identified). Effi-
cacy criteria will not be accounted for in the dose alloca-
tion process in case of a second AED requirement before 
T41/4 or an unexpected event in LEV preparation or infu-
sion precipitating an unknown dose injection.
Toxicity criteria and safety monitoring
Toxicity will be assessed according to both of the following 
modalities: (i) short-term toxicity and (ii) long-term 
toxicity (figure 2). Short-term toxicity has been designed 
to rapidly trigger a decreasing dose allocation for the next 
potential participant through an e-CRF alert. Short-term 
toxicity focuses on four adverse events potentially attrib-
utable to LEV: (i) severe apnoea that leads to mechan-
ical ventilation during the 4 hour period following the 
LEV infusion;19 22 23 26 (ii) anaphylactic shock occurring 
during the 30 min following the LEV infusion;27 (iii) toxic 
epidermic necrosis and (iv) Stevens-Johnson syndrome. 
Investigators must declare the occurrence of one of these 
adverse events immediately to the pharmacovigilance 
unit and in the e-CRF. On day 6, if none of these adverse 
events have been observed, the investigator ticks the ‘no’ 
box that corresponds to each effect in the e-CRF and 
short-term toxicity will therefore be regarded as negative. 
Long-term toxicity encompasses all the adverse events 
observed and declared to the pharmacovigilance unit up 
to hospital discharge or the 30th day of life at the latest. 
A short-term toxicity alert or any serious unexpected 
suspected adverse reaction (SUSAR) will immediately 
trigger a meeting of the scientific committee, which 
consists of a pharmacist (CM) and a neonatologist (GF) 
and the LEV treatment will be discontinued. If no severe 
or unexpected adverse reactions are declared, a system-
atic meeting of the scientific committee will be planned 
during the 10 days following the participant discharge or 
the participant’s 30th day of life at the latest. The scien-
tific committee will then determine the imputability 
(unrelated/possible/probable) and acceptability of each 
declared adverse event based on the severity at the acute 
phase, the quality of recovery (partial or complete) with 
potential subsequent disability and the frequency of 
occurrence. Ultimately, a single adverse event regarded as 
imputable to LEV and inacceptable precipitates a decla-
ration of toxicity as positive in the statistical model. The 
requirement of another AED will also be included in the 
statistical model as well as the delay between T0 and treat-
ment beginning to the extent that it could alter proper 
LEV efficacy and toxicity.
secondary objectives
Pharmacokinetics of levetiracetam: blood samples
LEV PK in participant’s blood will be measured five 
times at 30 min, 4 hours and 7 hours after the end of LEV 
loading dose infusion and at 1–3 hours and 12–18 hours 
after the last LEV maintenance dose (figure 2). Each 
PK sample requires 500 µL of total blood (ie, 2.5 mL in 
total). After centrifugation, the plasma will be harvested, 
and samples will be frozen at −20° or −80° before sending 
for measurement (VJ). The PK of LEV in the popula-
tion of the study will be investigated through a popula-
tion approach.31 The mean values of the PK parameters 
(elimination clearance, central and peripheral distribu-
tion volumes, distribution clearance) and their respec-
tive interindividual variability will be estimated. Possible 
relationships between the covariates (birth bodyweight, 
gestational age, therapeutic hypothermia) and the inter-
individual variability of the PK parameters will be inves-
tigated. Individual PK parameters will be estimated and 
used to calculated the maximum concentration and the 
area under curve (AUC) corresponding with the loading 
dose, after the first maintenance dose and the cumula-
tive AUC of the entire treatment. Potential relationships 
between these PK parameters and the efficacy and safety 
criteria will be investigated, and these pharmacokinetic/
pharmacodynamic relationships will be used to deter-
mine the optimal dosing regimen.
Seizure recurrence from T41/4 to day 6
Clinical or electric seizures occurrence and frequency 
during LEV treatment (ie, from T41/4 to T72) and until 
complete LEV elimination (ie, day 6) will be reported in 
the e-CRF in addition to concomitant AED treatment. 
The complete and definitive cessation of seizures will be 
recorded in the e-CRF. Continuous EEG monitoring is 
scheduled during the 3-day treatment by LEV as well as a 
1 hour recording on day 6. Unfortunately, the restricted 
availability of EEG devices in each investigating centre 
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after the cessation of SB prompted a minimal require-
ment of a 1 hour EEG recording on days 1, 2, 3 and 6 
after the LEV treatment initiation. Then, the detection of 
seizure recurrence and the duration of EEG monitoring 
are then under the responsibility of each investigator.
Pretreatment seizure burden and LEV efficacy
PB and PHT efficacy in relation to complete seizure 
control have been directly associated with the pretreat-
ment burden seizure intensity.7 Therefore, to explore this 
association with LEV, a new analysis will be performed 
retrospectively by adjusting the efficacy criteria to the SB 
on the pretreatment EEG. Two subgroups will be consid-
ered based on the SB intensity on the pretreatment EEG 
equal to or above 50% of the EEG recording duration 
(high SB group) and strictly under 50% of the duration 
(low SB group). LEV efficacy will be deemed positive 
when a SB reduction of 50% is observed on the post-treat-
ment EEG recording in the high SB group, whereas a 
reduction of 80% will still be valid for the low SB group.
Patient follow-up
The participant follow-up will continue until hospital 
discharge or until the 30th day of life. An assessment has 
been planned that consists of repeated clinical exam-
inations, haemodynamic monitoring, brain-imaging 
and auditory and electroencephalographic recordings 
(figure 2). Clinical examinations will be performed at 
days 1, 2, 3 and 6 through the Thompson score,32 which 
measures the neurological distress depth. In addition, 
Amiel-Tison scoring,33 focusing on neurological status of 
the newborn, is planned to occur on hospital discharge 
or on the 30th day of life. Arterial pressure and heart rate 
will be measured immediately before each LEV injec-
tion and every 5 min for 15 min, and then every 15 min 
for 45 min after the LEV injection. Apnoea, bradycardia 
under 80 beats per minute, and oxygen saturation drops 
below 85% will be reported. Brain MRI will be performed 
between the 4th and 8th day of life. An auditory evoked 
potential measurement will also be required before 
hospital discharge.
other AEd requirements
If the persistence or recurrence of seizures is observed after 
the LEV loading dose, the investigators are completely 
free to initiate another antiepileptic treatment. The drug 
name, administered dose, therapeutic schedule and treat-
ment duration will be reported in the e-CRF. If another 
AED is required during the 4 hours following the LEV 
loading dose ends, the efficacy data will not be included 
in the statistical model.
lEV treatment cessation rules
LEV treatment will have to be discontinued in any of 
the following cases: (i) a short-term toxicity or a SUSAR 
occurs; (ii) serum creatinine raises above 150 µmol/L in 
the 7–36 hours interval following the LEV loading dose; 
(iii) a complete unknown LEV loading dose was infused 
due to a hazardous event; (iv) a mistaken maintenance 
dose above 60 mg/kg was infused; (v) a limitation of 
intensive cares begins before the third day of LEV treat-
ment or (vi) at least one of the two parents or authorised 
guardians withdraws his consent.
statistical model and dose allocation
LEVNEONAT-1 is an open-label, single group, sequen-
tial dose-finding study with four increasing dosage 
levels. The short-term toxicity, long-term toxicity and 
the efficacy endpoints were modelled under Bayesian 
inference. The optimal dose of LEV was defined as the 
highest efficient dose under the toxicity restrictions. 
Before the beginning of the trial, efficacy and toxicity 
thresholds associated with the desirable optimal dose 
have been selected. The optimal dose should not be 
associated with less than 60% of efficacy probability and 
no more than 10% of short-term and long-term toxicity 
probabilities. After the inclusion of successive cohorts 
of two patients, the endpoint observations are bina-
rised as follows: efficacy (yes or no), short-term toxicity 
(yes or no and, if yes, when), long-term toxicity (yes or 
no), other AED use (yes or no and if yes, when) and 
the number of infused maintenance doses with timing 
(figure 1). A statistical model was designed specifically 
for this trial, because no other dose-allocation method 
was available for this indication. The model is a sequen-
tial adaptive method since it incorporates all the avail-
able information before the trial onset and all the data 
from the trial that have been accumulated for each 
new cohort inclusion. Based on updated data, proba-
bilities of efficacy, short-term and long-term toxicities 
are re-estimated after each cohort. The dose allocated 
to each further cohort is the estimated as the optimal 
dose known thus far. The first cohort of patients will 
receive the lowest dose level, and doses will be increased 
one-by-one based on the model estimates (no dose-skip-
ping will be allowed if the dose was not yet evaluated). 
Moreover, since long-term toxicity will take an extended 
time to be observed, a time to event approach will be 
considered to avoid ceasing inclusions between two 
successive cohorts.
When a short-term toxicity alert occurs, a reduc-
tion of the current loading dose allocated to the lower 
level is planned until the scientific committee’s conclu-
sion concerning LEV imputability or lack thereof. The 
maximal sample size is expected to be 50 participants 
with a minimum of 24 patients. However, the trial will 
be terminated prematurely if all doses do not reach 
the efficacy threshold or the lowest dose exceeds the 
toxicity threshold. When a patient is eligible, the current 
dose regimen is available on the trial sponsor’s web site. 
This dose will be renewed in real time according to the 
previous participants’ data.
Independent data-monitoring committee
An independent data-monitoring committee (DMC) 
has been established, which includes a neonatologist, 
a neuropaediatrician and a pharmacologist. A DMC 
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opinion concerning the trial continuation will be solic-
ited every six patients or in the case of an emergency on 
the request of the scientific committee.
trial interruption criteria
Three criteria have been identified for trial interruption: 
(i) a high probability of incorrect dose range (either for 
efficacy or for toxicity) will cause a temporary interrup-
tion of the trial. After the IMC consultation, a new range 
of doses could be proposed; (ii) new valid information 
is published during LEVNEONAT-1, which addresses the 
principal aim and render this trial outdated or (iii) the 
scientific committee can decide to terminate the trial at 
any time if an unacceptable toxicity is assigned to LEV.
Patient and public involvement
Patients and the public were not involved in the design 
of the study.
EthICs
LEV cannot be infused prior to obtaining the written 
parental or authorised guardian’s consent. One of two 
parents or authorised guardians can withdraw their 
consent at any time, prompting the interruption of the 
newborn participation in LEVNEONAT-1. Safety moni-
toring would still be performed to ensure adequate 
treatment of potential LEV side effects but it will not be 
recorded in the database. An authorisation from parents 
or authorised guardians will be necessary to use the data 
obtained before the agreement withdrawal.
Ethical approval for this study (version 4, 06-06-2017) 
has been obtained from the regional ethical committee 
(CPP Ouest 1) under the reference 2016-R25 on the 
9 November 2016. The French drug safety agency (Agence 
Nationale de la Sécurité du Médicament) approved 
LEVNEONAT-1 (version 4, 06-06-2017) under the refer-
ence 160652A-31 on the 5 October 2016.
This trial has been registered on EudraCT (20 February 
2014) and on Clinical  Trial. gov (1 September 2014). The 
Eudra CT reference is 2014-000791-26 and the  Clinical-
Trials. gov reference is NCT02229123. Trial registration 
data are reported in table 1.
dAtA quAlIty
Standardised LEV prescriptions have been designed in 
an Excel format. These documents have been joined to 
the allocation-dose web site. Therefore, the investigator 
will only fill in the allocated dose and the participant’s 
birth weight to obtain personalised LEV prescriptions 
(dilution, quantity, infusion speed, monitoring). For each 
included participant, all data will be anonymised under 
a specific code (centre city and number of inclusion), 
and a personalised file (e-CRF) will be created on the 
trial sponsor’s web site (https:// chu- tours. hugo- online. 
fr/ CSOnline/). Data will be reported in the participant’s 
e-CRF accessible with a personal code (lead investigator). 
Lead investigators will only have access to the e-CRFs 
of their own centre. Only the coordinating investigator 
(GF), scientific committee members (GF, CM) and data 
manager (EB) have access to all participants’ data. Data 
will be checked by faxing original paper documents 
(drug prescriptions, vital-sign monitorings, biological 
measurements, EEG interpretations) to the trial sponsor. 
An agent (EB) will be assigned by the sponsor (ie, Univer-
sitary Hospital Center of Tours) for meeting the lead 
investigators and local research teams regularly, based on 
the inclusion dynamic. These on-site visits aim to monitor 
the regular filing of consent forms, the compliance with 
the protocol and the accuracy of the recorded data from 
source documents. An audit trigger by the French Drug 
Safety Agency could be possible at any time during the 
trial course. Data management have been validated 
through the MR-001 reference methodology.
dIssEMInAtIon
Any modifications to the protocol that might impact 
the conduct of the study or affect patient safety will 
precipitate a substantive protocol amendment and will 
be reviewed by the regional Ethics Committee and the 
French Drug Safety Agency. These substantive changes 
will be communicated to relevant stakeholders (trial 
registries, regulatory agencies, investigators). The results 
of the LEVNEONAT-1 study will be published in a peer-re-
viewed journal following the Uniform Requirements for 
Manuscripts Submitted to Bio-medical Journals (http://
www. icmje. org/). Publications will be distributed to inves-
tigational centres and to all relevant persons or organi-
sations. The LEVNEONAT-1 study will also be presented 
at relevant national and international medical and scien-
tific meetings related to both of the following elements: 
(i) methodology and biostatistics and (ii) brain develop-
ment and seizure treatment during the neonatal period. 
At the end of the study, a summary of the results will be 
produced for the non-medical public and will be provided 
to the participants’ parents on demand.
tIME-lInE
Investigational centres were open from the 21 September 
2017 to the 20 October 2017. Patient recruitment was 
effective from the 20 October 2017 for 2 years. The first 
enrolment occurred in February 2018.
dIsCussIon
Seizure management during the neonatal period remains 
elusive, and PHB is not completely efficient in termi-
nating critical activity and is not truly safe for the imma-
ture brain. LEV might be promising and more suitable in 
this condition. However, although LEV is widely used in 
neonatal care units worldwide, no dose regimen has been 
clearly established.
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LEVNEONAT-1 is a particularly original study using 
LEV as the first-line treatment and not as add-on treat-
ment after PHB, resulting in purer efficacy and safety 
data and allowing the possibility of a new therapeutic 
schedule in neonates.
The other original characteristic of LEVNEONAT-1 is 
the design of a statistical model allowing for a restricted 
sample size to determine the optimal LEV dose in 
neonates by integrating data in real time of each partic-
ipant. The design performances were assessed through 
extensive simulation studies. On average, the proposed 
design prompts recommendations of the correct dose 
at approximately 60% of efficacy for a sample size of 30, 
increasing to over 80% in many scenarios for a sample 
size of 50. Moreover, this method maintains an acceptable 
number of neonates with toxicities.
Table 1 LEVNEONAT-1 trial registration data
Data category Information
Primary registry and trial identifying number ClinicalTrials.gov NCT02229123
Date of registration in primary registry 1 September 2014
Secondary identifying numbers EudraCT 2014-000791-26
Source of monetary or material support French Ministry of Health
Primary sponsor French Ministry of Health
Secondary sponsor European Union’s Seventh Framework Programme for research
Contact for public queries GF (email address)
Contact for scientific queries GF
Public title Levetiracetam efficacy and safety as first-line treatment of neonatal seizures 
occurring in hypoxic-ischaemic encephalopathy context
Scientific title Levetiracetam optimal dose-finding as first-line treatment for neonatal seizures 
occurring in the context of hypoxic-ischaemic encephalopathy (LEVNEONAT-1): 
study protocol of a phase II trial
Country of recruitment France
Health condition(s) or problem(s) studied Antiepileptic drug, neonatal seizures
Intervention Experimental drug: levetiracetam
Key inclusion and exclusion criteria Age eligible for study: newborns born after 36 gestational weeks and weighting 
more than 1800 g at birth
Inclusion criteria: perinatal asphyxia signs, abnormal neurological examination on 
the first 6 hours of life; clinical or electrical seizures occurring before 72 hours of 
life; 8-electrode standard EEG available
Exclusion criteria: newborns already treated with an antiepileptic drug, 
seizures secondary to treatable metabolic abnormalities (ie, hypoglycaemia, 
hypocalcaemia), serum creatine concentration above 150 µmol/l; congenital 
malformation or genetic syndrome, proven infectious embryofetopathy, 
participation to another interventional trial
Study type Interventional
Allocation: single arm, open study, four increasing dose regimens, two-patient 
cohort per dose level
Primary purpose: optimal-dose finding, efficacy and safety
Phase II
Date of first enrolment February 2018
Target sample size 50
Recruitment status Recruiting
Primary outcomes Efficacy: seizure-burden reduction of 80% after loading dose on EEG recording
Safety: short-term and long-term toxicities
Key secondary outcomes Pharmacokinetic analysis through five times (ie, 30 min, 4 hours and 7 hours from 
the loading dose, 1–3 hours and 12–18 hours from the last maintenance dose)
Seizure recurrence
Pretreatment seizure burden and levetiracetam efficacy
EEG, electroencephalogram.
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The first LEVNEONAT-1 weakness is the targeted popu-
lation, which consists of newborns with less than 3 days of 
life who suffer from HIE complicated with seizures. The 
seizure incidence in the HIE context varies according 
to studies from 29% to 65% of cases.34–36 This discrep-
ancy might be partially due to the caregiver’s ability to 
recognise clinical signs of seizure and ictal activity on an 
EEG recording.37–39 In parallel, the relative urgency to 
obtain parental consent in this stressful context remains 
a sensitive issue for investigators. This fact could be a crit-
ical point for inclusion because seizures can occur early 
after birth and therefore require AED treatment in emer-
gency. Both parents should then be informed soon after 
birth even prior to seizure occurrence, and the reflec-
tion period of participants’ guardians could be brief. 
However, the median time of the first seizures reported in 
the literature was around 9 to 13 hours of life,34 40 allowing 
for time for reflection to the parents. The second crit-
ical point is the opportunity to monitor the newborns 
through a standard EEG as soon as seizures are identi-
fied with various logistical problems according to each 
investigational centre, including a variable delay or the 
inability to implement standard EEG monitoring outside 
of working hours. Further, continuous EEG monitoring 
is scheduled during the 3-day treatment with LEV and a 
1 hour recording on day 6. The restricted availability of 
EEG devices in each investigating centre led after the 
cessation of SB to a minimal requirement of a 1 hour EEG 
recording on days 1, 2, 3 and 6.
In the case of promising efficacy results, a randomised 
study should be performed further to confirm the findings.
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